Fluvoxamine is a well-tolerated, widely available, inexpensive selective serotonin reuptake
inhibitor that has been shown in a small, double-blind, placebo-controlled, randomized …

COVID-19, the disease responsible for the devastating pandemic that began at the end of
2019, has been associated with a significantly increased risk of pulmonary thrombosis, even …

COVID-19 is a highly heterogeneous and complex medical disorder; indeed, severe COVID-
19 is probably amongst the most complex of medical conditions known to medical science …

Severe acute respiratory syndrome coronavirus 2 is responsible for coronavirus disease
2019 (COVID‐19). While COVID‐19 is often benign, a subset of patients develops severe …

In 2019 first reports about a new human coronavirus emerged, which causes common cold
symptoms as well as acute respiratory distress syndrome. The virus was identified as severe …

Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can
lead to a variety of clinical outcomes, ranging from the absence of symptoms to severe acute …

As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread
globally, it became evident that the SARS-CoV-2 virus infects multiple organs including the …

Antidepressants have previously been associated with better outcomes in patients
hospitalized with COVID-19, but their effect on clinical deterioration among ambulatory …

Mechanisms of immunothrombosis in COVID-19 : Current Opinion in Hematology
Mechanisms of immunothrombosis in COVID-19 : Current Opinion in Hematology Log in or …

Viral infections are often associated with platelet activation and haemostatic complications.
In line, low platelet counts represent a hallmark for poor prognosis in many infectious …